Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial

Michelle L. O'Donoghue, Eugene Braunwald, Harvey D. White, Dylan P. Steen, Mary Ann Lukas, Elizabeth Tarka, P. Gabriel Steg, Judith S. Hochman, Christoph Bode, Aldo P. Maggioni, Kyung Ah Im, Jennifer B. Shannon, Richard Y. Davies, Sabina A. Murphy, Sharon E. Crugnale, Stephen D. Wiviott, Marc P. Bonaca, David F Watson, W. Douglas Weaver, Patrick W. SerruysChristopher P. Cannon, SOLID-TIMI 52 Investigators, P. E. Aylward, S. A. Chen, B. Lewis, J. Anderson, M. Freeman, R. Lehman, P. Roberts-Thomson, D. Lee

    Research output: Contribution to journalArticlepeer-review

    263 Citations (Scopus)

    Abstract

    IMPORTANCE: Lipoprotein-associated phospholipase A2(Lp-PLA2) has been hypothesized to be involved in atherogenesis through pathways related to inflammation. Darapladib is an oral, selective inhibitor of the Lp-PLA2enzyme. OBJECTIVE: To evaluate the efficacy and safety of darapladib in patients after an acute coronary syndrome (ACS) event. DESIGN, SETTING, AND PARTICIPANTS: SOLID-TIMI 52was a multinational, double-blind, placebo-controlled trial that randomized 13 026 participants within 30 days of hospitalization with an ACS (non-ST-elevation or ST-elevationmyocardial infarction [MI]) at 868 sites in 36 countries. INTERVENTIONS: Patients were randomized to either once-daily darapladib (160mg) or placebo on a background of guideline-recommended therapy. Patients were followed up for a median of 2.5 years between December 7, 2009, and December 6, 2013. MAIN OUTCOMES AND MEASURES: The primary end point (major coronary events)was the composite of coronary heart disease (CHD) death, MI, or urgent coronary revascularization formyocardial ischemia. Kaplan-Meier event rates are reported at 3 years. RESULTS: During a median duration of 2.5 years, the primary end point occurred in 903 patients in the darapladib group and 910 in the placebo group (16.3%vs 15.6%at 3 years; hazard ratio [HR], 1.00 [95%CI, 0.91-1.09]; P = .93). The composite of cardiovascular death, MI, or stroke occurred in 824 in the darapladib group and 838 in the placebo group (15.0%vs 15.0%at 3 years; HR, 0.99 [95%CI, 0.90-1.09]; P = .78). There were no differences between the treatment groups for additional secondary end points, for individual components of the primary end point, or in all-cause mortality (371 events in the darapladib group and 395 in the placebo group [7.3%vs 7.1%at 3 years; HR, 0.94 [95%CI, 0.82-1.08]; P = .40). Patients were more likely to report an odor-related concern in the darapladib group vs the placebo group (11.5%vs 2.5%) and also more likely to report diarrhea (10.6%vs 5.6%). CONCLUSIONS AND RELEVANCE: In patients who experienced an ACS event, direct inhibition of Lp-PLA2with darapladib added to optimal medical therapy and initiated within 30 days of hospitalization did not reduce the risk of major coronary events. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01000727

    Original languageEnglish
    Pages (from-to)1006-1015
    Number of pages10
    JournalJAMA - Journal of the American Medical Association
    Volume312
    Issue number10
    DOIs
    Publication statusPublished - 10 Sep 2014

    Keywords

    • Darapladib
    • acute coronary syndrome
    • atherogenesis
    • Lipoprotein-associated phospholipase A2 (Lp-PLA2)
    • Lp-PLA2 enzyme

    Fingerprint Dive into the research topics of 'Effect of darapladib on major coronary events after an acute coronary syndrome: The SOLID-TIMI 52 randomized clinical trial'. Together they form a unique fingerprint.

    Cite this